Navigation Links
Nektar to Announce Financial Results for the First Quarter of 2011 on Wednesday, April 27, 2011, After Close of U.S.-Based Financial Markets
Date:4/18/2011

SAN FRANCISCO, April 18, 2011 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter ended March 31, 2011 on Wednesday, April 27, 2011, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Wednesday, May 25, 2011. To access the conference call, follow these instructions:Dial: (800) 573-4754 (U.S.); (617) 224-4325 (international)Passcode: 88966725 (Nektar Therapeutics is the host)An audio replay will also be available shortly following the call through Wednesday, May 25, 2011 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 92209339.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug cand
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... -- Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) ... results of the Phase 3 Rocket 1 trail of ... to meet its end points, compelling data from the ... studies. An analyst report on AERI that ... analyst summary, valuation, and recommendation can be viewed by ...
(Date:4/30/2015)... Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its first quarter ended March 31, ... quarter of 2015 was $116.2 million, up $14.5 million ... down $5.3 million or 4.4% from the fourth quarter ... as reported in accordance with U.S. generally accepted accounting ...
(Date:4/30/2015)... 30, 2015  Tandem Diabetes Care ® , Inc. (NASDAQ: ... the t:slim ® and t:flex™ Insulin Pumps, today reported ... In comparing the first quarter of 2015 ... 53 percent to $12.3 million from $8.1 million , ... 1,723 pumps "Our investment in resources to build ...
Breaking Medicine Technology:All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6
... A new study published online today ... NEJM) shows bevacizumab (Avastin) is as effective as ranibizumab ... treating age-related macular degeneration (AMD). The ... Trials" (CATT) study, a pioneering comparative effectiveness trial made ...
... 2011 PharmaNet Development Group, Inc., a leading provider ... and medical device companies, announced today that Valerie Palumbo ... Quality Assurance. "We are very pleased ... President, PharmaNet Development Group. "Valerie brings deep experience in ...
Cached Medicine Technology:Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 2Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 3Cleveland Clinic-Led Study Finds Bevacizumab as Effective as FDA-Approved Ranibizumab in Treating Macular Degeneration 4
(Date:5/3/2015)... 03, 2015 Leading international program provider, ... will be awarding the 2015 Harris Wofford Global Service ... Ghebrendrias, are the deserving recipients of the award named ... Harris Llewellyn Wofford. The two recipients were chosen for ... global health. , CFHI is one of seven ...
(Date:5/3/2015)... Missouri (PRWEB) May 03, 2015 ... business that will directly impact your career? The ... designed for dynamic leaders in multinational companies and ... company. In a changing global landscape, differences in ... and relationships. The EMIB program develops the global ...
(Date:5/3/2015)... May 03, 2015 HealthPostures, a ... solutions, announces its appearance at the , May 5 ... that HealthPostures will exhibit at the conference include its ... sit stand solutions is the 6100 TaskMate Executive. Features ... control, an adjustable keyboard tray, extended platform work surface ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 “ ActOn ” ... which takes a look at the latest and coolest applications ... the host of AppWatch and technology expert, conducted the app ... to get connected with organizations to make a difference. , ... are very few things that aren’t about money, which is ...
(Date:5/2/2015)... May 02, 2015 “ Peachtree Audio ... monthly Tech Report, which features the latest and coolest ... expert and special reporter for NewsWatch, conducted the review ... audio equipment. , Music is an important part ... be pampered and given the royal treatment. Peachtree Audio ...
Breaking Medicine News(10 mins):Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2
... vice minister of health in China has sought for more ... organs by patients in their country//. According to him there ... and the actual donations. ,Statistics reveal that 1.5 ... are lucky enough to find organs. In China organs are ...
... come out in support of old wisdom, in order ... health challenges// of today. ,Improving pupil-teacher ... very ethos(institutional culture) of a school will do the ... superiority of aged principles to newer ones such ...
... research conducted by Dr Michael Kisley, a psychologist from the ... more positive// outlook towards life than young people. These findings ... than one hundred and fifty participants took part in this ... neutral and negative aspects of life. The viewing was restricted ...
... on antiretroviral therapy (ART) experience liver enzyme elevation ... advised when prescribing ART in this population. Results ... Antiretrovirals) study indicate that coinfection itself may be ... ,The study investigated whether coinfected individuals on ...
... of AZT, lamivudine, and nevirapine (AZT/3TC/NVP) taken from week ... delivery resulted in significantly reduced HIV levels in breast ... the breast milk of women who were not treated ... Enhancement Against AIDS and Malnutrition) in Mozambique conducted this ...
... The use of medicines to fight cardiovascular disease has been ... past several decades,// as combinations of interventions and medicinal therapy ... ,Two studies has looked at the measurable impact of ... demonstrates that lower doses of therapies may prove to be ...
Cached Medicine News:Health News:'School Sermons' Need a Comeback 2Health News:Study Attributes Elevated Liver Enzymes in HIV/hepatitis to Coinfection Rather Than Antiretrovirals 2Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 2Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 3Health News:Triple ARV Prophylaxis Reduces Viral Load in Breast Milk 4Health News:Low-dose Aspirin Beats High-dose After Cardiac Surgery 2Health News:Low-dose Aspirin Beats High-dose After Cardiac Surgery 3
... Knife with BD Xstar Blade includes a ... the blade in prodedure and handling. ... a grind-less process for manufacturing surgical blades. ... and consistency. The arch style, single-bevel ...
Consists of the print and PDA versions of Harrison's Manual of Medicine 15th Edition. Provides high-end medical content via PDA....
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists....
... The SphygmoCor Mx Central Blood ... of the SphygmoCor Px system by ... aortic pressure waveform., ,Key cardiovascular parameters ... trended. These parameters include:, Central ...
Medicine Products: